iptacopan

Details

Generic Name:
iptacopan
Project Status:
Pending
Therapeutic Area:
paroxysmal nocturnal hemoglobinuria (PNH)
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Call for patient/clinician input open:
Brand Name:
TBD
Project Line:
Reimbursement Review
Project Number:
SR0851-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
​The treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH) who have an inadequate response to, or are intolerant of, a C5 inhibitor
Fee Schedule:
Pending
Indications:
The treatment of adult patients with paroxysmal nocturnal hemoglobinuria (PNH)
Anticipated Date:
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.